Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis.

In a recent genome-wide association study, variants in 8 genes were associated with VWF level, a risk factor for venous thrombosis (VT). In an independent, population-based, case-control study of incident VT, we tested hypotheses that variants in these genes would be associated with risk. Cases were 656 women who experienced an incident VT, and controls comprised 710 women without a history of VT. DNA was obtained from whole blood. Logistic regression was used to test associations between incident VT and single nucleotide polymorphisms (SNPs) in 7 genes not previously shown to be associated with VT. Associations with P < .05 were candidates for replication in an independent case-control study of VT in both sexes. Two of the 7 SNPs tested yielded P < .05: rs1039084 (P = .005) in STXBP5, a novel candidate gene for VT, and rs1063856 (P = .04) in VWF, a gene whose protein level is associated with VT risk. Association results for the remaining 5 variants in SCARA5, STAB2, STX2, TC2N, and CLEC4M were not significant. Both STXBP5 and VWF findings were replicated successfully. Variation in genes associated with VWF levels in the genome-wide association study was found to be independently associated with incident VT.

[1]  Ming-Huei Chen,et al.  Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand Factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium , 2010, Circulation.

[2]  T. Lumley,et al.  Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. , 2009, American journal of hypertension.

[3]  T. Lumley,et al.  ABO genotype and risk of thrombotic events and hemorrhagic stroke , 2009, Journal of thrombosis and haemostasis : JTH.

[4]  K. Lunetta,et al.  Methods in Genetics and Clinical Interpretation Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Design of Prospective Meta-Analyses of Genome-Wide Association Studies From 5 Cohorts , 2010 .

[5]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[6]  P. Reitsma,et al.  Gene variants associated with deep vein thrombosis. , 2008, Journal of the American Medical Association (JAMA).

[7]  K. Mossman The Wellcome Trust Case Control Consortium, U.K. , 2008 .

[8]  A. Hofman,et al.  The Rotterdam Study: objectives and design update , 2007, European Journal of Epidemiology.

[9]  A. Folsom,et al.  Factor VII coagulant activity, factor VII −670A/C and −402G/A polymorphisms, and risk of venous thromboembolism , 2007, Journal of thrombosis and haemostasis : JTH.

[10]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[11]  Meena Kumari,et al.  Lifecourse influences on health among British adults: effects of region of residence in childhood and adulthood. , 2007, International journal of epidemiology.

[12]  T. Lumley,et al.  Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. , 2007, JAMA.

[13]  L. O'Brien,et al.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. , 2007, Blood.

[14]  M. Yamakuchi,et al.  Regulation of Weibel-Palade body exocytosis. , 2005, Trends in cardiovascular medicine.

[15]  Joseph A. Smith,et al.  Malignancies, prothrombotic mutations, and the risk of venous thrombosis. , 2005, The Journal of urology.

[16]  A. Malik,et al.  Protease-activated Receptor-1 Activation of Endothelial Cells Induces Protein Kinase Cα-dependent Phosphorylation of Syntaxin 4 and Munc18c , 2005, Journal of Biological Chemistry.

[17]  A. Reiner,et al.  Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. , 2004, JAMA.

[18]  A. Hofman,et al.  Determinants of disease and disability in the elderly: The Rotterdam elderly study , 1991, European Journal of Epidemiology.

[19]  J. Goudemand,et al.  Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. , 2001, Best practice & research. Clinical haematology.

[20]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[21]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[22]  David C. Atkins,et al.  The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. , 1994, Archives of internal medicine.

[23]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[24]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[25]  C. Patel TM AND HYPERTENSION , 1976, The Lancet.

[26]  W. Kannel,et al.  The Framingham Offspring Study. Design and preliminary data. , 1975, Preventive medicine.

[27]  S. Shapiro,et al.  VENOUS THROMBOEMBOLIC DISEASE AND ABO BLOOD TYPE. A COOPERATIVE STUDY , 1969 .

[28]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.